Caris Life Sciences, Inc.
Close on Nov 20, 2026Market cap $4.97BP/E –Yield –
Caris Life Sciences Adjusted EBITDA: $44.4M in Q3 2026, down 13.2% from a year earlier.
Where the Q3 2026 figure comes from
“Adjusted EBITDA | $ | 44,420 | $ | 51,167 | $ | 126,322 | $ | 31,665”
Source: SEC Form 8-K Ex 99.1 — Q3 2026 Financial Results (filed 2026-11-04) ↗
Net income (loss) adjusted to exclude interest income/expense, fair value changes on financial instruments, other income/expense (incl. debt extinguishment), taxes, D&A, and stock-based compensation.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Caris Life Sciences Adjusted EBITDA ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Caris Life Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/cai/kpis/adjusted-ebitda-m
See every metric in the Caris Life Sciences KPI table. Data updated Nov 16, 2026.
See a number that looks wrong?